Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
"MERCK SHARP & DOHME (NEW ZEALAND) LIMITED, Consumer",Pembrolizumab Lenvatinib,"advanced clear cell renal cell carcinoma, first line",Pembrolizumab Lenvatinib (Keytruda Lenvima),Only if cost neutral or cost saving,,Oncology Agents and Immunosuppressants
